Kirsten Haman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kirsten Haman has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Allison G. Harvey
University of California, Berkeley, Berkeley, USA
1 shared publication - Armando Martinez
University of California, Berkeley, CA, USA
1 shared publication - Benjamin B. Brodey
TeleSage, Inc., 201 East Rosemary St., Chapel Hill, NC 27514, USA
1 shared publication - Claire Weaver
Department of Psychology, University of California, Berkeley, 3210 Tolman Hall #1650, Berkeley, CA, 94720-1650, USA
1 shared publication - Courtney C. Armstrong
Clinical Instructor, Department of Psychiatry and Behavioral Sciences, Division of Child and Adolescent Psychiatry and Child Development, Stanford University
1 shared publication - David Ayer
4100 N. Rosewood Drive, Bloomington, IN 47404, USA
1 shared publication
Latest Publications
- Open Access
- 14 November 2017
- Published by Springer Nature in Trials
- Vol. 18 (1) , 1-11
Can integrating the Memory Support Intervention into cognitive therapy improve depression outcome? Study protocol for a randomized controlled trial
The Memory Support Intervention was developed in response to evidence showing that: (1) patient memory for treatment is poor, (2) poor memory for treatment is associated with poorer adherence and poorer outcome, (3) the impact of memory impairment can be minimized by the use of memory support strategies and (4) improved memory for treatment improves outcome. The aim of this study protocol is to conduct a confirmatory efficacy trial to test whether the Memory Support Intervention improves illness course and functional outcomes. As a “platform” for the next step in investigating this approach, we focus on major depressive disorder (MDD) and cognitive therapy (CT). Adults with MDD (n = 178, including 20% for potential attrition) will be randomly allocated to CT + Memory Support or CT-as-usual and will be assessed at baseline, post treatment and at 6 and 12 months’ follow-up (6FU and 12FU). We will compare the effects of CT + Memory Support vs. CT-as-usual to determine if the new intervention improves the course of illness and reduces functional impairment (aim 1). We will determine if patient memory for treatment mediates the relationship between treatment condition and outcome (aim 2). We will evaluate if previously reported poor treatment response subgroups moderate target engagement (aim 3). The Memory Support Intervention has been developed to be “transdiagnostic” (relevant to a broad range of mental disorders) and “pantreatment” (relevant to a broad range of types of treatment). This study protocol describes a “next step” in the treatment development process by testing the Memory Support Intervention for major depressive disorder (MDD) and cognitive therapy (CT). If the results are promising, future directions will test the applicability to other kinds of interventions and disorders and in other settings. ClinicalTrials.gov, ID: NCT01790919 . Registered on 6 October 2016.
- 14 November 2017
- Published by Springer Nature in Trials
- Vol. 18 (1) , 1-11
Open AccessCan integrating the Memory Support Intervention into cognitive therapy improve depression outcome? Study protocol for a randomized controlled trial
The Memory Support Intervention was developed in response to evidence showing that: (1) patient memory for treatment is poor, (2) poor memory for treatment is associated with poorer adherence and poorer outcome, (3) the impact of memory impairment can be minimized by the use of memory support strategies and (4) improved memory for treatment improves outcome. The aim of this study protocol is to conduct a confirmatory efficacy trial to test whether the Memory Support Intervention improves illness course and functional outcomes. As a “platform” for the next step in investigating this approach, we focus on major depressive disorder (MDD) and cognitive therapy (CT). Adults with MDD (n = 178, including 20% for potential attrition) will be randomly allocated to CT + Memory Support or CT-as-usual and will be assessed at baseline, post treatment and at 6 and 12 months’ follow-up (6FU and 12FU). We will compare the effects of CT + Memory Support vs. CT-as-usual to determine if the new intervention improves the course of illness and reduces functional impairment (aim 1). We will determine if patient memory for treatment mediates the relationship between treatment condition and outcome (aim 2). We will evaluate if previously reported poor treatment response subgroups moderate target engagement (aim 3). The Memory Support Intervention has been developed to be “transdiagnostic” (relevant to a broad range of mental disorders) and “pantreatment” (relevant to a broad range of types of treatment). This study protocol describes a “next step” in the treatment development process by testing the Memory Support Intervention for major depressive disorder (MDD) and cognitive therapy (CT). If the results are promising, future directions will test the applicability to other kinds of interventions and disorders and in other settings. ClinicalTrials.gov, ID: NCT01790919 . Registered on 6 October 2016.
- Open Access
- 1 April 2016
- Published by Elsevier in Comprehensive Psychiatry
- Vol. 66, 67-70
Validation of the NetSCID: an automated web-based adaptive version of the SCID
- 1 April 2016
- Published by Elsevier in Comprehensive Psychiatry
- Vol. 66, 67-70
Open AccessValidation of the NetSCID: an automated web-based adaptive version of the SCID
- 31 May 2009
- Published by Elsevier in Cognitive and Behavioral Practice
- Vol. 16 (2) , 153-163
Ethical Considerations for Cognitive-Behavioral Therapists in Psychotherapy Research Trials
- 31 May 2009
- Published by Elsevier in Cognitive and Behavioral Practice
- Vol. 16 (2) , 153-163
Ethical Considerations for Cognitive-Behavioral Therapists in Psychotherapy Research Trials
- 1 April 2008
- Vol. 6 (4) , 155-63
Psychologic distress and head and neck cancer: part 1--review of the literature.
Patients with head and neck cancer (HNC) experience a variety of psychiatric symptoms and disorders, possibly at rates greater than those seen in patients with other types of cancer. This paper reviews the literature on psychologic distress in HNC patients and will also focus on symptoms and diagnoses of depression, anxiety, and substance abuse--conditions requiring the involvement of healthcare professionals. An awareness of the type of issues experienced by HNC patients is vital for accurate assessment and effective intervention.
- 1 April 2008
- Vol. 6 (4) , 155-63
Psychologic distress and head and neck cancer: part 1--review of the literature.
Patients with head and neck cancer (HNC) experience a variety of psychiatric symptoms and disorders, possibly at rates greater than those seen in patients with other types of cancer. This paper reviews the literature on psychologic distress in HNC patients and will also focus on symptoms and diagnoses of depression, anxiety, and substance abuse--conditions requiring the involvement of healthcare professionals. An awareness of the type of issues experienced by HNC patients is vital for accurate assessment and effective intervention.